Abstract
The common classes of antibiotics used to treat UTIs that clinicians should be familiar with include penicillin, cephalosporin, carbapenems, fluoroquinolones, aminoglycosides, and fosfomycin. These are explored further below and summarised in Table 4.1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70(9):2456–64.
Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquinolones: a critical review. Can J Infect Dis. 1999;10(3):207–38.
Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029.
DTB. Fosfomycin for UTIs. Drug Ther Bull. 2016;54:114–7.
Avent ML, Rogers BA, Cheng AC, Athan E, Francis JR, Roberts MJ, Paterson DL, Harris PNA. Fosfomycin: what was old is new again. Intern Med J. 2018 Dec;48(12):1425–9.
Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–47.
Mehta D, Sharma AK. Cephalosporins: a review on imperative class of antibiotics. Invent Rapid Mol Pharmacol. 2016;1:1–6.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943–60.
Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570–84.
Wagenlehner FME, Naber KG. Cefiderocol for treatment of complicated urinary tract infections. Lancet Infect Dis. 2019;19(1):22–3.
Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018;11:1461–72.
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018;18:1319–28.
Choi JJ, McCarthy MW. Cefiderocol: a novel siderophore cephalosporin. Expert Opin Investig Drugs. 2018;27(2):193–7.
EAU guidelines. Urological infections. https://uroweb.org/guideline/urological-infections/. Accessed 1 Jan 2019.
NICE guidelines. Urinary tract infection (lower)—women. https://cks.nice.org.uk/urinary-tract-infection-lower-women. Accessed 1 Jan 2019.
Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200(6):1174–91.
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;3:CD001209.
Price JR, Guran LA, Gregory WT, et al. Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;215:548.
Ahmed H, Davies F, Francis N, Farewell D, Butler C, Paranjothy S. Long-term antibiotics for prevention of recurrent urinary tract infection in older adults: systematic review and meta-analysis of randomised trials. BMJ Open. 2017;7(5):e015233.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Phan, Y.C., Yang, B. (2020). Antibiotics. In: Yang, B., Foley, S. (eds) Female Urinary Tract Infections in Clinical Practice. In Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-27909-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-27909-7_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-27908-0
Online ISBN: 978-3-030-27909-7
eBook Packages: MedicineMedicine (R0)